PF

Phil Ferneau

Investor at Ankyra Therapeutics

Hanover, New Hampshire

Overview

Work Experience

  • Co-Founder and Managing Partner

    2002 - Current

    Early-stage healthcare venture capital firm, with a focus on life science platforms, digital health, and animal health opportunities.

  • Board Director and Investor

    2014

    Antibody therapeutics to treat cancer (Nasdaq: CMPX)

  • Board Director and Investor

    2021

    Intratumoral immunotherapy.

  • Investor and Former Board Director

    2020

    Genetics-informed antibody therapies for I&I disorders.

  • Board Director and Investor

    2019

    Redefining the role of genomic laboratories in delivering better healthcare.

  • Investor and Former Board Director

    2020

    Platform company developing novel TCR therapies for cancer and autoimmune disease.

  • Board Director and Investor

    2018

    Peptide discovery platform company spun out from the University of Oxford

  • Board Observer and Investor

    2018

    The future of clinical research.

  • Investor

    2008

    Premier human antibody discovery and humanization.

  • Investor

    2018

    Transformative exosome therapeutics.

Relevant Websites